|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes:a randomized,double-blind,placebo-controlled study显示文摘 | Pratley RE Reusch JEB Fleck PR | 2009 | Curr Med Res Opin2009，25，10： | 1 |
| 2 | Protective effect of alpha - tocopherol in head and neck cancer radiation - in?duced mucositis: a double - blind randomized trial显示文摘 | Ferreira PR Fleck JF Diehl A | 2004 | Head Neck2004，26，4： | 1 |
| 3 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glybufide monotherapy 显示文摘 | Pratley RE Kipnes MS Fleck PR | 2009 | Diabetes Obes Metab2009，11，2： | 1 |
| 4 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, doubleblind, placebo-controlled study 显示文摘 | DeFronzo RA Fleck PR Wilson CA | 2008 | Diabetes Care2008，31，12： | 1 |
| 5 | Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies 显示文摘 | Pratley RE McCall T Fleck PR | 2009 | J Am Geriatr Soc2009，57，11： | 1 |
| 6 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes : a randomized, double-bfind, placebo- controlled study显示文摘 | Pratley RE Reusch JE Fleck PR | 2009 | Curr Med Res Opin2009，25，10： | 1 |
| 7 | Efficacy and safety ofthe dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type2 diabetes and inadequate glycemic control:a randomized double-blind,placebo-controlled study显示文摘 | DeFronzo RA Fleck PR Wilson CA | 2008 | Diabetes Care2008，31，12： | 1 |
| 8 | Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes : the LEAD ( liraglutide effect and ac- tion in diabetes) -2 study显示文摘 | Nauck M Ellis GC Fleck PR | 2009 | Diabetes Care2009，32，1： | 1 |
| 9 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control : a randomized, double- blind, placebo-controlled study 显示文摘 | DeFronzo RA Fleck PR Wilson CA | 2008 | Diabetes Care2008，31，12： | 1 |
| 10 | Efficacy and safety of the dipeptidy 1 peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double blind, placebo-controlled study显示文摘 | Defronzo RA Fleck PR Wilson CA | 2008 | Diabetes Care2008，31，12： | 1 |
| 11 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes : a randomized, double-blind, placebo-controlled study显示文摘 | Pratley RE Reusch JE Fleck PR | 2009 | Curt Med Res Opin2009，25，10： | 1 |
| 12 | Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy : a multicentre, randomised, double-blind, placebo-controlled study 显示文摘 | Nauck MA Ellis GC Fleck PR | 2009 | Int J Clin Pract2009，63，1： | 1 |
| 13 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy 显示文摘 | Pratley RE Kipnes MS Fleck PR | 2009 | Diabetes Obes Metab2009，11，2： | 1 |
| 14 | Radiofrequency catheter ablation for the treatment of human type I atrial flutter显示文摘 | Feld GK Fleck PR Chen PS | 1992 | Circulation1992，86，： | 1 |
| 15 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study显示文摘 | Defronzo RA Fleck PR Wilson CA | 2008 | Diabetes Care2008，31，12： | 1 |
| 16 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy显示文摘 | PRATLEY RE KIPNES MS FLECK PR | 2009 | Diabetes Obes Metab2009，11，2： | 1 |
| 17 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control:a randomized,double-blind,placebo-controlled study显示文摘 | DeFronzo RA Fleck PR Wilson CA | 2008 | Diabetes Care2008，31，： | 1 |
| 18 | Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy:a multicentre,randomised,double-blind,placebo-controlled study显示文摘 | Nauck MA Ellis GC Fleck PR | 2009 | Int J Clin Pract2009，63，： | 1 |
| 19 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy显示文摘 | Pratley RE Kipnes MS Fleck PR | 2009 | Diabetes Obes Metab2009，11，： | 1 |
| 20 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes:a randomized,double-blind,placebo-controlled study显示文摘 | Pratley RE Reusch JE Fleck PR | 2009 | Curr Med Res Opin2009，25，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员